Advertisement

Topics

Neos Therapeutics Announces FDA Approval Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old

20:00 EDT 19 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Neos Therapeutics Announces FDA Approval Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old

NEXT ARTICLE

More From BioPortfolio on "Neos Therapeutics Announces FDA Approval Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old"

Advertisement
Quick Search
Advertisement
Advertisement